NEW YORK--(BUSINESS WIRE)--Feb. 21, 2006--Neuro-Hitech Pharmaceuticals, Inc. (OTC BB: NHPI), a drug development company engaged in the development and commercialization of Huperzine A (HupA) and its analogues for a variety of degenerative neurological disorders, today announced that it has appointed Mark Auerbach Chairman of its Board of Directors. Also, the Company has appointed John D. Abernathy to its board, and he will chair the audit committee. Both appointments were effective upon Neuro-Hitech's merger with Northern Way Resources, Inc. This brings the total number of directors to 4, two of whom are outside directors.
